RNS Number : 4700A
Immupharma PLC
02 June 2021
 

 

 

RNS: RELEASE                                                                                                                                                  2 JUNE 2021

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Notice of AGM and posting of Report & Accounts

 

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2020, and the Notice of Annual General Meeting has been posted to shareholders.

 

These documents are available, in electronic form, for download on the Company's website www.immupharma.co.uk.

 

ImmuPharma's Annual General Meeting (AGM) will be held on Monday, 28 June 2021 @ 10.30am (BST) at: 25 Wilton Road, Victoria, London SW1V 1LW.

Government guidance in the UK relating to COVID-19 continues to place restrictions on public gatherings, so shareholders will not be permitted to attend the AGM in person. The AGM will therefore be held with the minimum attendance necessary to form a quorum (which will be facilitated by the Company).

In light of those measures, we strongly encourage you to consider ensuring your vote is counted by submission of the proxy by post. Please complete the paper proxy that accompanies this notice and return it to the Company's Registrar, Computershare Investor Services plc, The Pavilions, Bridgwater Road, Bristol, BS99 6ZY. All proxy forms must be received by no later than 48 hours prior to the AGM, being 10:30am on Thursday 24 June 2021.

Investor Meet Company | Virtual Participation

In order to ensure that shareholders are able to follow the proceedings of the AGM, the Company will provide a live broadcast of the AGM through the Investor Meet Company ("IMC") platform. However, shareholders will not be able to vote online during the AGM and are therefore urged to submit their votes via proxy as early as possible. Shareholders are also invited to submit written questions for the Board to consider. Questions can be pre-submitted in advance of the AGM via the IMC platform up to 09:00am on 25 June 2021, being the working day before the AGM, or via the IMC platform at any time during the AGM itself. The Board will respond to key questions during the meeting and will provide such answers via the IMC platform thereafter. Shareholders who wish to attend the AGM online should register for the event in advance via the following link: https://www.investormeetcompany.com/immupharma-plc/register-investor

 

Ends

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

John Howes

Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

 

Degroof Petercam (Liquidity Provider)

Erik De Clippel

 

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60

 

 

+32 (0) 2 287 95 34

 

 

 

+32 (0) 477 504 784

+32 (0) 475 903 909

 

 

 

 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk 

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFBMITMTTMBPB ]]>